News Center

位置：

Honors Announcement

Group News

Media Reports

Intellectual Property Service Platform Supports Further Research on Arbidol

Category:

Group News

发布时间：2020-06-04

【概要描述】 Recently, Shijiazhuang Sihua Pharmaceutical Co., Ltd. signed a contract with the National Intellectual Property Operation Public Service Platform. Under the terms of the agreement, Shijiazhuang Sihua will be entitled to free access for one year to the big-data thematic database on “Arbidol and its salt-based pharmaceutical formulations and analytical methods.”

Recently, Shijiazhuang Sihua Pharmaceutical Co., Ltd. signed a contract with the National Intellectual Property Operation Public Service Platform. Under the terms of the agreement, Shijiazhuang Sihua will be entitled to free access for one year to the big-data thematic database on “Arbidol and its salt-based pharmaceutical formulations and analytical methods.”

In response to General Secretary Xi’s call to intensify scientific research efforts in COVID-19 prevention and control, and in active implementation of the relevant measures outlined in the “Several Measures for Strengthening Collaborative Research on Novel Coronavirus–Induced Pneumonia and Enhancing Scientific and Technological Support for Emergency Pandemic Response,” the National Intellectual Property Operation Public Service Platform (hereinafter referred to as the “Service Platform”) is soliciting applications from research institutions, universities, and enterprises for the Service Platform’s “Patent Operation Specialized Database” project. The Service Platform will provide, free of charge, the construction of big-data specialized databases on relevant technical topics for eligible applicant entities. Research institutions, universities, and enterprises that have contributed to COVID-19 prevention and control efforts or conducted emergency research on related issues are all welcome to apply. Upon selection, the Service Platform will build the corresponding specialized database on the relevant technical topic for each applicant at no cost, and the applicant will be entitled to use the database free of charge for a period of one year.

According to available information, the National Intellectual Property Operation Public Service Platform is a pilot project initiated under the leadership of the National Intellectual Property Administration and in collaboration with the Ministry of Finance, in line with the key task outlined in the National 13th Five-Year Plan to “accelerate the development of a nationwide intellectual property operation, trading, and service platform and build a country strong in intellectual property.” As the core platform of the national “1+N” intellectual property operation system, it will provide platform support for patent transfer and commercialization, acquisition and trusteeship, trading and circulation, pledge-based financing, patent navigation, and other related activities, thereby enhancing the efficiency of patent utilization.

Abidor is the flagship product of Shijiazhuang Sihua Pharmaceutical. During the pandemic, the company’s employees remained steadfast on the front lines of producing and supplying anti-epidemic medications, working overtime to ensure uninterrupted Abidor production and supply, thereby making outstanding contributions to epidemic prevention and control and earning widespread public acclaim.

During the battle against COVID-19, arbidol has played a positive role. Consequently, further research and redevelopment of arbidol have become key priorities for enterprises. The recently submitted big-data thematic database project on “Arbidol and Its Salt-Based Pharmaceutical Preparations and Associated Testing Methods” has been successfully selected, which will provide more scientific and comprehensive information to support the reevaluation of this drug and facilitate related research endeavors.

Keywords:

Tian Jianing, a member of the Standing Committee of the CPC Cangzhou Municipal Committee and Head of the United Front Work Department, Conducts a Research Visit to Guangxiang Pharmaceutical, a Subsidiary of Shisiyao Group

Niu Xuejian, Deputy Director of the Shijiazhuang Municipal Administration for Market Regulation, Conducts a Research Visit to Shijiazhuang Sihua Pharmaceutical on Intellectual Property Work